Segment Disclosure (Tables)

3 Months Ended

Mar. 31, 2025

Segment Reporting [Abstract]

Summary of Net Loss Related To Segment Expenses

The following table presents information about reported segment revenues, significant segment expenses, and segment loss:

	Three Months Ended March 31,
	2025			2024
Collaboration revenue	$	7,500		$	—
Less:
Direct external research and development costs
Azetukalner		31,501			23,213
Pre-clinical, discovery and other programs		4,967			3,661
Personnel-related expenses		22,640			14,854
Stock-based compensation expense		12,174			9,400
Other research and development costs		3,425			3,014
Other general and administrative costs		5,531			4,899
Interest income		(8,083	)		(11,355	)
Other segment items(1)		392			245
Net loss	$	(65,047	)	$	(47,931	)

(1)Other segment items include foreign exchange gain and income tax expense.